Literature DB >> 25262563

Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro.

Tomoko Haruki1, Dai Miyazaki2, Kazuki Matsuura1, Yuki Terasaka1, Yumiko Noguchi1, Yoshitsugu Inoue1, Satoru Yamagami1.   

Abstract

PURPOSE: To evaluate and compare the toxic effects of moxifloxacin, cefuroxime, and levofloxacin on human corneal endothelial cells in vitro and determine the safe intracameral concentrations for them.
SETTING: Tottori University, Tottori, Japan.
DESIGN: Experimental study.
METHODS: Human corneal endothelial cells in culture were exposed to moxifloxacin, cefuroxime, and levofloxacin at concentrations up to 2000 μg/mL. Evaluation of membrane damage was determined by ethidium homodimer-1 uptake and cell viability, by intrinsic esterase activity. The inhibitory effects of the 3 antibiotics on the constitutive secretion of interleukin-6 (IL-6) by human corneal endothelial cells were determined by enzyme-linked immunosorbent assay.
RESULTS: The acute effects (6 hour) of the 3 antibiotics on membrane damage and cell death were dose-dependent for moxifloxacin and levofloxacin (≥ 500 μg/mL). For cefuroxime, membrane damage was not observed at 6 hours and only slight damage was detected at 24 hours at concentrations higher than 500 μg/mL. The half maximum inhibitory concentrations on cell viability of moxifloxacin, levofloxacin, and cefuroxime were 487 μg/mL, 578 μg/mL, and 1600 μg/mL, respectively. The inhibitory effects of the 3 antibiotics on the constitutive secretion of IL-6 were observed at 15.6 μg/mL or higher, indicating the antibiotics can impair the secretion of the protective cytokine even at low concentrations.
CONCLUSIONS: Moxifloxacin at more than 500 μg/mL caused damage to the cell membranes of corneal endothelial cells; even higher concentrations decreased cell viability. Considering the lower minimum inhibitory concentration for inhibiting 90% growth by moxifloxacin, intracameral moxifloxacin at 500 μg/mL or less is recommended for prophylactic use. FINANCIAL DISCLOSURE: Dr. Inoue is a medical advisor to Alcon Japan Ltd. No author has a financial or proprietary interest in any material or method mentioned.
Copyright © 2014 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25262563     DOI: 10.1016/j.jcrs.2014.08.027

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

1.  Injection volume and intracameral moxifloxacin dose.

Authors:  Neal H Shorstein; Susanne Gardner
Journal:  J Cataract Refract Surg       Date:  2019-08-20       Impact factor: 3.351

Review 2.  Drop-free approaches for cataract surgery.

Authors:  Neal H Shorstein; William G Myers
Journal:  Curr Opin Ophthalmol       Date:  2020-01       Impact factor: 4.299

3.  Endophthalmitis Prophylaxis Failures in Patients Injected With Intracameral Antibiotic During Cataract Surgery.

Authors:  Neal H Shorstein; Liyan Liu; James A Carolan; Lisa Herrinton
Journal:  Am J Ophthalmol       Date:  2021-02-08       Impact factor: 5.488

4.  Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells.

Authors:  Hitomi Miyake; Dai Miyazaki; Yumiko Shimizu; Shin-Ichi Sasaki; Takashi Baba; Yoshitsugu Inoue; Kazuki Matsuura
Journal:  Sci Rep       Date:  2019-07-05       Impact factor: 4.379

5.  Evaluation of moxifloxacin-induced cytotoxicity on human corneal endothelial cells.

Authors:  Joo-Hee Park; Martha Kim; Roy S Chuck; Choul Yong Park
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

6.  High dose cefuroxime causing retinal toxicity in a patient undergoing trabeculectomy.

Authors:  Jae Yee Ku; Shiao Wei Wong; Laura R Steeples; Claire Delaney; Neil R A Parry; Cecilia Fenerty
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-02

7.  Bidirectional effects of moxifloxacin on the pro‑inflammatory response in lipopolysaccharide‑stimulated mouse peritoneal macrophages.

Authors:  Zhenyu Qiu; Hongxia Yuan; Na Li; Xinjuan Yang; Xuemei Hu; Fengtai Su; Baiyi Chen
Journal:  Mol Med Rep       Date:  2018-10-22       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.